Factors affecting transmission of SARS-CoV-2 in Households of SARS-CoV-2 patients in Sub-Saharan Africa Ancillary study of the ANTICOV Study: An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild / moderate cases of COVID-19

Phase 3

Recruiting

• Conditions: COVID-19

• Registration Number: PACTR202010718451278
• Lead Sponsor: DNDi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-10-14
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 1500

Inclusion Criteria

For Index Cases (treated patients from the ANTICOV Study)
1.Comes from household in accessible area
2.At least 1 Household Contact (HHC) currently residing at household with index
3.Contact details of HHC provided by index case
4.Majority (over 50%) of HHC provide consent and enrol in the ANTICOV-EPI study
5.Randomised to ANTICOV
For Household contacts (not treated patients living with the Index patient)
6.Member of same household as index case (household defined as sharing same cooking area) during the conduct of the study
7.Resides in household with index case before index case illness onset.
8.Majority (over 50%) of HHC provide consent and enrol in the ANTICOV-EPI study

Exclusion Criteria

Exclusion criteria of household contacts
1.Inability to provide consent
2.Majority of all contacts of index in household do not enroll

Study & Design

• Study Type: Interventional
• Study Design: Not specified